Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Collaboration and License Agreements
Current portion of deferred revenue	$ 11,075	$ 9,387
Deferred revenue, net of current portion	5,215	8,113
GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”)
Collaboration and License Agreements
Deferred revenue		17,500
Fixed consideration amount		17,500
Research and collaboration revenue	1,200
Current portion of deferred revenue	11,100
Deferred revenue, net of current portion	$ 5,200
GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) | Maximum
Collaboration and License Agreements
Variable consideration amount, commercial sales milestones		$ 440,000